Lumenis partners with Mandy Moore on DED awareness

Article

The actress and singer-songwriter will serves as the brand ambassador for OptiLight, a new dry eye disease treatment.

Lumenis has launched a partnership with actress and singer-songwriter Mandy Moore as the new brand ambassador for OptiLight, the company’s bright solution for dry eyes. She is featured in a new OptiLight campaign, according to a news release.

OptiLight is the first and only light-based therapy for dry eye disease (DED) that uses a patented optimal pulse technology (OPT). It is designed to help improve DED symptoms with a series of quick, gentle, in-office treatments.

Moore’s partnership with Lumenis comes after she experienced signs and symptoms of DED. She said using OptiLight as treatment significantly improved her condition.

“I’m excited to partner with Lumenis and share how OptiLight has made a real impact on my life. For years, I suffered from dry eye disease, but I didn’t know I had it ... it was a constant frustration on the set and at home with my family,” Moore said, in a statement.

After being diagnosed wtih DED, Moore said receiving treatment from OptiLight allowed her to continue normal life.

"Now, I can focus more time on what’s important to me, rather than battling the constant nuisance and discomfort of dry eye disease, and I want to inspire other people to say, ‘I won’t just live with it,’” she said.

Learn more about OptiLight here

See more dry eye coverage

Recent Videos
Jessilin Quint, OD, MBA, FAAO, and Selina McGee, OD, FAAO
Jessilin Quint, OD, MBA, FAAO, and Selina McGee, OD, FAAO
Selina McGee, OD, FAAO, and Jessilin Quint, OD, MBA, FAAO
Selina McGee, OD, FAAO, and Jessilin Quint, OD, MBA, FAAO
Selina McGee, OD, FAAO, and Jessilin Quint, OD, MBA, FAAO
Selina McGee, OD, FAAO, and Jessilin Quint, OD, MBA, FAAO
Selina McGee, OD, FAAO, and Jessilin Quint, OD, MBA, FAAO
Selina McGee, OD, FAAO, and Jessilin Quint, OD, MBA, FAAO
Drs Erin Draper and Chris Cuk outline the important role optometrists have in spotting neurodegenerative disease in patients
© 2024 MJH Life Sciences

All rights reserved.